Search research articles
Contact Us
Filters
Showing results (311-320 of 539) with videos related to
Page
of 54
Sort By:
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|
June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma
Britta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Oncoimmunology
|
October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
Mohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
Blood
|
April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Jérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Leukemia & Lymphoma
|
November 15, 2011
MyelomA Genetics International Consortium
Gareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, et al.
Blood Cancer Journal
|
February 15, 2021
Characterization of rare germline variants in familial multiple myeloma
Calogerina Catalano, Nagarajan Paramasivam, Joanna Blocka, et al.
Blood Advances
|
October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Haematologica
|
October 2, 2010
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose, Thierry Rème, Thomas Hielscher, et al.
European Journal of Heart Failure
|
October 1, 2009
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
Arnt V Kristen, Falk-Udo Sack, Stefan O Schonland, et al.
The Lancet. Haematology
|
March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S Raab, Monika Engelhardt, Antje Blank, et al.
The Lancet. Oncology
|
August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Page
of 54
Search research articles
Search
Showing results (311-320 of 539) with videos related to
Sort By:
Page
of 54
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|
June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma
Britta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Oncoimmunology
|
October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
Mohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
Blood
|
April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Jérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Leukemia & Lymphoma
|
November 15, 2011
MyelomA Genetics International Consortium
Gareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, et al.
Blood Cancer Journal
|
February 15, 2021
Characterization of rare germline variants in familial multiple myeloma
Calogerina Catalano, Nagarajan Paramasivam, Joanna Blocka, et al.
Blood Advances
|
October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Haematologica
|
October 2, 2010
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose, Thierry Rème, Thomas Hielscher, et al.
European Journal of Heart Failure
|
October 1, 2009
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
Arnt V Kristen, Falk-Udo Sack, Stefan O Schonland, et al.
The Lancet. Haematology
|
March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S Raab, Monika Engelhardt, Antje Blank, et al.
The Lancet. Oncology
|
August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Page
of 54